Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

548 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia.
Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, Sureda A, Granell M, Vallansot R, Besses C, Montserrat E. Cervantes F, et al. Br J Haematol. 2006 Jul;134(2):184-6. doi: 10.1111/j.1365-2141.2006.06142.x. Epub 2006 Jun 1. Br J Haematol. 2006. PMID: 16740139 Free article. Clinical Trial.
Idiopathic myelofibrosis associated with ulcerative colitis.
Arellano-Rodrigo E, Esteve J, Giné E, Panés J, Cervantes F. Arellano-Rodrigo E, et al. Among authors: cervantes f. Leuk Lymphoma. 2002 Jul;43(7):1481-3. doi: 10.1080/1042819022386590. Leuk Lymphoma. 2002. PMID: 12389633
Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation.
Cervantes F, Hernández-Boluda JC, Odriozola J, Camós M, Villalón L, Martínez-Climent JA, del Campo R, García-Conde J, Montserrat E. Cervantes F, et al. Br J Haematol. 2003 Feb;120(3):500-4. doi: 10.1046/j.1365-2141.2003.04077.x. Br J Haematol. 2003. PMID: 12580969 Free article. Clinical Trial.
Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F, Hernández-Boluda JC, Steegmann JL, Conde E, Alvarez-Larrán A, López-Jiménez J, Osorio S, Villalón L, Camós M, García-Conde J, Odriozola J. Cervantes F, et al. Haematologica. 2003 Oct;88(10):1117-22. Haematologica. 2003. PMID: 14555307 Clinical Trial.
548 results